CF
BLTE

Convergence Financial’s Belite Bio BLTE Stock Holding History

Convergence Financial’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$473K Buy
+2,968
New +$499K 0.05% 149

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Convergence Financial's BLTE Position: Q1 2026 in Review

Convergence Financial opened a new position in Belite Bio (BLTE) in Q1 2026: 2,968 shares worth $473K. The stake represents 0.05% of the portfolio and ranks #149 among its holdings.

75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Convergence Financial held 2,968 shares of Belite Bio worth $473K as of Q1 2026.
  • Belite Bio was a new Convergence Financial position in Q1 2026.
  • Belite Bio made up 0.05% of Convergence Financial's portfolio in Q1 2026, its #149 holding.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Convergence Financial's 13F filing for Q1 2026, filed 11 May 2026.